NICE issues draft guidance (Final Appraisal Document) on ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (CDF review of TA593)
In DRAFT guidance, NICE recommends ribociclib plus fulvestrant as an option for treating hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy, according to the stated criteria.
Source:
National Institute for Health and Care Excellence
SPS commentary:
This appraisal reviewed additional evidence collected as part of the Cancer Drugs Fund managed access agreement, which suggests that when compared with fulvestrant alone, people taking ribociclib plus fulvestrant have longer progression-free and overall survival. A related press release notes that this treatment could be an option for up to 3,300 women.